These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22322320)

  • 1. Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy.
    Tong CC; Lau KH; Rivera M; Cannan D; Aguirre-Ghiso J; Sikora AG; Gupta V; Forsythe K; Ko EC; Misiukiewicz K; Gurudutt V; Teng MS; Packer SH; Genden EM; Kao J
    Oncol Rep; 2012 May; 27(5):1580-6. PubMed ID: 22322320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
    Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
    Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
    Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
    Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
    Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation.
    Ko EC; Genden EM; Misiukiewicz K; Som PM; Kostakoglu L; Chen CT; Packer S; Kao J
    Oncol Rep; 2012 Feb; 27(2):467-74. PubMed ID: 22020564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).
    Fury MG; Sherman EJ; Rao SS; Wolden S; Smith-Marrone S; Mueller B; Ng KK; Dutta PR; Gelblum DY; Lee JL; Shen R; Kurz S; Katabi N; Haque S; Lee NY; Pfister DG
    Ann Oncol; 2014 Mar; 25(3):689-694. PubMed ID: 24496920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
    Kies MS; Haraf DJ; Athanasiadis I; Kozloff M; Mittal B; Pelzer H; Rademaker AW; Wenig B; Weichselbaum RR; Vokes EE
    J Clin Oncol; 1998 Aug; 16(8):2715-21. PubMed ID: 9704722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
    Kies MS; Haraf DJ; Rosen F; Stenson K; List M; Brockstein B; Chung T; Mittal BB; Pelzer H; Portugal L; Rademaker A; Weichselbaum R; Vokes EE
    J Clin Oncol; 2001 Apr; 19(7):1961-9. PubMed ID: 11283128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
    Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.
    Karam SD; Reddy K; Blatchford PJ; Waxweiler T; DeLouize AM; Oweida A; Somerset H; Marshall C; Young C; Davies KD; Kane M; Tan AC; Wang XJ; Jimeno A; Aisner DL; Bowles DW; Raben D
    Clin Cancer Res; 2018 Oct; 24(20):4949-4959. PubMed ID: 30084837
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
    Haraf DJ; Kies M; Rademaker AW; Stenson K; Mittal B; Pelzer H; Wenig B; Witt ME; Sulzen L; Weichselbaum RR; Vokes EE
    J Clin Oncol; 1999 Feb; 17(2):638-44. PubMed ID: 10080609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Niu X; Hu C; Kong L
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):1063-71. PubMed ID: 23525586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
    Argiris A; Haraf DJ; Kies MS; Vokes EE
    Oncologist; 2003; 8(4):350-60. PubMed ID: 12897332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
    Brockstein B; Haraf DJ; Stenson K; Fasanmade A; Stupp R; Glisson B; Lippman SM; Ratain MJ; Sulzen L; Klepsch A; Weichselbaum RR; Vokes EE
    J Clin Oncol; 1998 Feb; 16(2):735-44. PubMed ID: 9469365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
    Habl G; Jensen AD; Potthoff K; Uhl M; Hof H; Hajda J; Simon C; Debus J; Krempien R; Münter MW
    BMC Cancer; 2010 Nov; 10():651. PubMed ID: 21108850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
    Milano MT; Vokes EE; Kao J; Jackson W; List MA; Stenson KM; Witt ME; Dekker A; MacCracken E; Garofalo MC; Chmura SJ; Weichselbaum RR; Haraf DJ
    Int J Oncol; 2006 May; 28(5):1141-51. PubMed ID: 16596230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
    Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE
    Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMRT-SIB with concurrent and neo-adjuvant platinum-based chemotherapy for locally advanced head and neck squamous cell cancer: analysis of clinical outcomes in a retrospective series of a single institution.
    Mazzeo E; Antognoni P; Parmiggiani M; D'Ambrosio C; De Marco G; Marra L; Gottardi G; Bertoni F
    Tumori; 2014; 100(6):652-9. PubMed ID: 25688499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
    Qian W; Zhu G; Ji Q; Guo Y; Wang Y; Wang Y
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):217-22. PubMed ID: 24785284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.